Evidence map›Paper›PMID 35409195›Full record

ReviewInternational journal of molecular sciences2022

Exploring the FGF/FGFR System in Ocular Tumors: New Insights and Perspectives.

Alessandra Loda, Marta Turati, Francesco Semeraro, Sara Rezzola, Roberto Ronca

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Alessandra LodaDepartment of Molecular and Translational Medicine, School of Medicine, University of Brescia, 25123 Brescia, Italy.
Marta TuratiDepartment of Molecular and Translational Medicine, School of Medicine, University of Brescia, 25123 Brescia, Italy.ORCID 0000-0002-7139-3820
Francesco SemeraroEye Clinic, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, 25123 Brescia, Italy.ORCID 0000-0002-2275-4917
Sara RezzolaDepartment of Molecular and Translational Medicine, School of Medicine, University of Brescia, 25123 Brescia, Italy.ORCID 0000-0003-1193-8929
Roberto RoncaDepartment of Molecular and Translational Medicine, School of Medicine, University of Brescia, 25123 Brescia, Italy.ORCID 0000-0001-8979-7068
University of Brescia · IT

Funding

Italian Association for Cancer Research IG grant n° 23151
6 · The paper itself

Abstract

Ocular tumors are a family of rare neoplasms that develop in the eye. Depending on the type of cancer, they mainly originate from cells localized within the retina, the uvea, or the vitreous. Even though current treatments (e.g., radiotherapy, transpupillary thermotherapy, cryotherapy, chemotherapy, local resection, or enucleation) achieve the control of the local tumor in the majority of treated cases, a significant percentage of patients develop metastatic disease. In recent years, new targeting therapies and immuno-therapeutic approaches have been evaluated. Nevertheless, the search for novel targets and players is eagerly required to prevent and control tumor growth and metastasis dissemination. The fibroblast growth factor (FGF)/FGF receptor (FGFR) system consists of a family of proteins involved in a variety of physiological and pathological processes, including cancer. Indeed, tumor and stroma activation of the FGF/FGFR system plays a relevant role in tumor growth, invasion, and resistance, as well as in angiogenesis and dissemination. To date, scattered pieces of literature report that FGFs and FGFRs are expressed by a significant subset of primary eye cancers, where they play relevant and pleiotropic roles. In this review, we provide an up-to-date description of the relevant roles played by the FGF/FGFR system in ocular tumors and speculate on its possible prognostic and therapeutic exploitation.

Indexed as

Eye NeoplasmsReceptors, Fibroblast Growth FactorFibroblast Growth FactorsHumansNeovascularization, PathologicSignal TransductionFibroblast Growth FactorsReceptors, Fibroblast Growth FactorFGFFGFRocular tumorsretinoblastomauveal melanoma

Identifiers

PMID35409195
PMCPMC8998873
OpenAlexW4220707306

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.